Zheng Fu, Yang Liu, Hui Yang, Weiwei Xiong, Xue Yin, Weifang Fang, Xiuting Li, Xixiang Wei, Jianzhang Hu
{"title":"Comprehensive analysis of clinical phenotype and genetic characteristics of retinoblastoma caused by <i>RB1</i> gene mutation: a case series.","authors":"Zheng Fu, Yang Liu, Hui Yang, Weiwei Xiong, Xue Yin, Weifang Fang, Xiuting Li, Xixiang Wei, Jianzhang Hu","doi":"10.62347/GVHN8345","DOIUrl":null,"url":null,"abstract":"<p><p>This study aimed to summarize the clinical and genetic characteristics of retinoblastoma associated with newly identified RB1 gene mutations. We retrospectively analyzed 15 pediatric patients diagnosed with retinoblastoma caused by RB1 mutations. A total of 25 affected eyes were examined (8 males, 7 females). The age at diagnosis ranged from 7 to 36 months (mean 16.00 ± 8.61 months). Bilateral involvement was observed in 10 patients, and unilateral in 5. Thirteen patients presented with leukocoria, while 2 were diagnosed during routine physical examinations due to vision loss. None of the patients had a family history of retinoblastoma. Whole-exome sequencing revealed heterozygous RB1 mutations in 14 cases and a mosaic mutation in one case. Five novel mutations not previously reported in the literature were identified: c.608-1G>A, c.1818T>A, c.962dupA, c.2086A>T, and c.574A>T. All patients received treatment, including intra-arterial chemotherapy, cryotherapy, photocoagulation, systemic chemotherapy, and/or enucleation. The follow-up duration ranged from 12 to 132 months, with a mean of 39.20 ± 24.07 months. Genetic testing remains a valuable tool for confirming RB1 mutations. Expanding the RB1 mutation spectrum may facilitate early diagnosis, personalized treatment, and informed genetic counseling for affected children.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 5","pages":"2332-2337"},"PeriodicalIF":2.9000,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12163462/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/GVHN8345","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
This study aimed to summarize the clinical and genetic characteristics of retinoblastoma associated with newly identified RB1 gene mutations. We retrospectively analyzed 15 pediatric patients diagnosed with retinoblastoma caused by RB1 mutations. A total of 25 affected eyes were examined (8 males, 7 females). The age at diagnosis ranged from 7 to 36 months (mean 16.00 ± 8.61 months). Bilateral involvement was observed in 10 patients, and unilateral in 5. Thirteen patients presented with leukocoria, while 2 were diagnosed during routine physical examinations due to vision loss. None of the patients had a family history of retinoblastoma. Whole-exome sequencing revealed heterozygous RB1 mutations in 14 cases and a mosaic mutation in one case. Five novel mutations not previously reported in the literature were identified: c.608-1G>A, c.1818T>A, c.962dupA, c.2086A>T, and c.574A>T. All patients received treatment, including intra-arterial chemotherapy, cryotherapy, photocoagulation, systemic chemotherapy, and/or enucleation. The follow-up duration ranged from 12 to 132 months, with a mean of 39.20 ± 24.07 months. Genetic testing remains a valuable tool for confirming RB1 mutations. Expanding the RB1 mutation spectrum may facilitate early diagnosis, personalized treatment, and informed genetic counseling for affected children.
期刊介绍:
The American Journal of Cancer Research (AJCR) (ISSN 2156-6976), is an independent open access, online only journal to facilitate rapid dissemination of novel discoveries in basic science and treatment of cancer. It was founded by a group of scientists for cancer research and clinical academic oncologists from around the world, who are devoted to the promotion and advancement of our understanding of the cancer and its treatment. The scope of AJCR is intended to encompass that of multi-disciplinary researchers from any scientific discipline where the primary focus of the research is to increase and integrate knowledge about etiology and molecular mechanisms of carcinogenesis with the ultimate aim of advancing the cure and prevention of this increasingly devastating disease. To achieve these aims AJCR will publish review articles, original articles and new techniques in cancer research and therapy. It will also publish hypothesis, case reports and letter to the editor. Unlike most other open access online journals, AJCR will keep most of the traditional features of paper print that we are all familiar with, such as continuous volume, issue numbers, as well as continuous page numbers to retain our comfortable familiarity towards an academic journal.